



14th February, 2022

To,
The General Manager
Department of Corporate Services - CRD
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai 400 001

Dear Sir,

Sub: Outcome of Board Meeting – Quarterly Results

Dear Sir,

Further to our letter dated 3rd February, 2022, we would like to inform that the Board of Directors of the Company at its meeting held today ie; 14th February, 2022 at 07.00 P.M and concluded at 8.00 P.M., have approved the Un-Audited Financial Results for the quarter ended 31st December, 2021.

In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following:


1. Un-Audited Consolidated Financial Results for the Quarter ended 31st December, 2021.
2. Un-Audited Standalone Financial Results for the quarter ended 31st December, 2021.
3. Auditors' Report on the Standalone and Consolidated Financial Results for the Quarter.

Please take note that the opinion given by the Statutory Auditor in the Enclosed Audit Report for the Quarter is unmodified opinion.

We kindly request you to take the same on record.

Thanking You,
Yours Sincerely,
For **DECIPHER LABS LIMITED**

Kumar Raghavan
**COMPANY SECRETARY &
COMPLIANCE OFFICER**



DECIPHER LABS LIMITED

(Formerly known as Combat Drugs Limited) (CIN CL23230TG1986PLC006781)

Regd. off: 4th Floor, Plot No.94, Sagar Society, Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-48536100

Consolidated Unaudited Financial Results For the Quarter and Nine months ended 31 December, 2021

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter ended			Nine months ended		Year ended
	31.12.2021	30.09.2021	31.12.2020	31.12.2021	31.12.2020	31.03.2021
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	1,371.24	1,492.62	1,373.69	4,203.47	4,147.01	5,556.22
II. Other income	730.37	9.69	4.41	751.13	31.67	64.56
III. Total revenue (I + II)	2,101.61	1,502.31	1,378.10	4,954.60	4,178.68	5,620.78
IV. Expenses						
Purchase of Stock-in-Trade	15.53	-	-	15.53	11.40	15.04
Changes in inventories of finished goods and stock in trade	-	-	-	-	1.61	27.45
Employee benefits expense	1,241.97	1,189.33	1,100.81	3,577.74	3,544.34	4,748.47
Finance costs	13.59	7.66	29.69	33.76	100.19	113.34
Depreciation and amortisation expense	22.35	22.24	20.13	66.82	60.15	81.93
Other expenses	55.06	137.52	202.42	270.28	360.71	420.26
Total expenses	1,348.50	1,356.75	1,353.05	3,964.13	4,078.40	5,406.49
V. Profit/(Loss) before tax (III - IV)	753.11	145.56	25.05	990.47	100.28	214.29
VI. Tax expense:						
(1) Current tax	67.55	51.22	15.45	119.95	40.40	73.70
(2) Deferred tax	(42.33)	(55.64)	(0.77)	(73.73)	(1.87)	(1.30)
(3) Tax of earlier years	(0.00)	0.76	-	0.76	-	1.63
VII. Profit/(Loss) for the period (V-VI)	727.89	149.22	10.37	943.49	61.75	140.26
VIII. Other comprehensive income						
Items that will be reclassified to statement of profit and loss	-	-	-	-	-	-
Exchange differences on translating the financial statements of foreign Subsidiaries	4.77	(4.22)	1.13	20.35	28.96	(27.57)
IX. Total comprehensive income for the year	732.66	145.00	11.50	963.84	90.71	112.69
Paid Up Equity Share Capital (FV of Rs 10 each)	1,010.00	1,010.00	1,010.00	1,010.00	1,010.00	1,010.00
X. Earning per equity share						
(1) Basic	7.21	1.48	0.10	9.34	0.61	1.39
(2) Diluted	7.21	1.48	0.10	9.34	0.61	1.39

Notes

1. The operations of the Group relate to two segments viz., Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.

Segment Information:

Particulars	Quarter ended			Nine months ended		Year Ended
	31.12.2021	30.09.2021	31.12.2020	31.12.2021	31.12.2020	31.03.2021
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Segment Revenue						
a) Manufacturing and Trading of Pharmaceutical drugs	30.02	-	18.54	30.02	48.91	43.70
b) Consultancy Services	1,341.22	1,492.62	1,359.56	2,833.84	4,129.77	5,512.52
Total Sales	1,371.24	1,492.62	1,378.10	2,863.86	4,178.68	5,556.22
Less: Inter Segment Revenue	-	-	-	-	-	-
Total Revenue from Operations	1,371.24	1,492.62	1,378.10	2,863.86	4,178.68	5,556.22

Cont..2

Segment Result (Profit Before Tax and Interest from each Segment)						
a) Manufacturing and Trading of Pharmaceutical drugs	6.65	-	0.77	6.65	2.36	2.58
b) Consultancy Services	760.05	165.73	53.97	925.78	198.11	325.05
Total	766.70	165.73	54.74	1,024.22	200.47	327.63
Less: Interest	13.59	20.17	29.69	33.76	100.19	113.34
Total Profit before tax	753.11	145.56	25.05	990.47	100.28	214.29
Capital employed (Segment assets - segment liabilities)						
Segment assets						
a) Manufacturing and trading of Pharmaceutical drugs	279.54	276.79	313.15	279.54	313.15	298.31
b) Consultancy Services	4,003.62	3,685.86	2,761.70	4,003.62	2,761.70	3,573.82
Total Assets	4,283.16	3,962.65	3,074.85	4,283.16	3,074.85	3,872.13
Segment liabilities						
a) Manufacturing and trading of Pharmaceutical drugs	17.20	21.54	31.47	17.20	31.47	19.63
b) Consultancy Services	1,933.37	2,341.65	1,754.53	1,933.37	1,754.53	2,483.78
Total Liabilities	1,950.57	2,363.19	1,786.00	1,950.57	1,786.00	2,503.41

2. The above results for the Quarter and half year ended 31 December 2021 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 14.02.2022.

3. The financial results of the Group have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

4. The group has considered the possible effects that may result from the pandemic relating to Covid-19 in the preparation of these financial statements including the recoverability of carrying amounts of financial and non-financial assets. In developing the assumptions relating to the possible future uncertainties in the global economic conditions because of this pandemic, the Company has, at the date of approval of these financial statements, used internal and external sources of information including credit reports and related information and economic forecasts and expects that the carrying amount of these assets will be recovered. The impact of Covid-19 on the Group's financial statements may differ from that estimated as at the date of approval of these financial statements.

5. The above results include results of wholly owned subsidiaries

- i) ICP Solutions Private Limited, India
- ii) Decipher Software Solutions LLC, USA

6. The Group has consolidated financial results based on Ind AS 110 "Consolidated Financial Statements".

7. Comparative figures have been regrouped/reclassified to conform to the current period's/year's presentation.

For and on behalf of the Board



Sushant Mohan Lal
Director
DIN: 01227151



Place: Hyderabad
Date: 14.02.2022



Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Review Report to The Board of Directors Decipher Labs Limited
(Formerly Known as Combat Drugs Limited)

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Decipher Labs Limited ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter and nine months ended 31st December, 2021 ("the Statement"), being submitted by the Holding pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.


We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following subsidiaries:
ICP Solutions Private Limited, India
Decipher Software Solutions LLC, USA
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the financial results of the subsidiaries referred to in paragraph 6 below nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



6. We did not review the interim financial results of two subsidiaries. i.e., Decipher Software Solutions LLC and ICP Solutions Private Limited included in the consolidated unaudited financial results whose interim financial results reflect total revenue of Rs. 2064.60 lakhs and Rs. 4881.56 lakhs, total net profit after tax of Rs.717.05 lakhs and Rs. 920.77 lakhs and total comprehensive profit of Rs. 717.05 lakhs and Rs. 920.77 lakhs for the quarter ended December 31, 2021 and for the period from April 01, 2021 to December 31, 2021 respectively, as considered in the consolidated unaudited financial results. These Interim financial results have been reviewed by other auditor's whose reports have been furnished to us by the Management and our conclusion on the consolidated financial results, in so far as it relates to the amounts and disclosure included in respect of these subsidiaries as based solely on the reports of such other auditor's and the procedures performed by us are as stated in the paragraph 3 above, our conclusion on the statement is not modified in respect of this matter.

For Ramanatham & Rao
Chartered Accountants
(Firm Regn.No.02934S)



K SREENIVASAN

Partner

Membership Number: 206421

UDIN: 22206421ACFDSF1743

Place: Secunderabad

Date: 14th February, 2022



DECIPHER LABS LIMITED

Formerly known as Combat Drugs Limited (CIN CL23230TG1986PLC006781)

Regd.off: 4th Floor , Plot No.94,Sagar Society, Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-48536100

Statement of Unaudited Standalone Financial Results For the Quarter and Nine Month Ended 31st December, 2021

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter ended			Nine months ended		Year ended
	31-12-2021	30-09-2021	31-12-2020	31-12-2021	31-12-2020	31-03-2021
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	37.45	18.58	18.54	74.38	60.41	97.60
II. Other income	0.46	0.55	0.46	1.37	1.36	14.43
III.Total revenue (I + II)	37.91	19.13	19.00	75.75	61.77	112.03
IV. Expenses						
Purchase of Stock in trade	15.53	-	0.00	15.53	11.40	15.04
Changes in inventories of finished goods and stock in trade	-	-	-	-	1.61	27.44
Employee benefits expense	5.09	7.02	3.65	18.85	16.05	19.85
Finance Costs	0.00	0.00	0.00	0.00	0.81	1.79
Depreciation and Amortisation expense	1.25	1.18	1.19	3.60	2.98	4.15
Other expenses	5.20	4.53	12.39	14.93	21.15	33.72
Total expenses	27.07	12.73	17.23	52.90	54.00	101.99
V. Profit before tax (III - IV)	10.84	6.40	1.77	22.85	7.77	10.04
VI. Tax expense:						
(1) Current tax	-	-	-	-	-	-
(2) Deferred tax	0.02	0.08	(0.29)	0.12	(0.26)	0.42
VII. Profit/(Loss) for the period (V-VI)	10.82	6.32	2.06	22.73	8.03	9.62
VIII. Other comprehensive income	-	-	-	-	-	-
IX. Total comprehensive income for the year	10.82	6.32	2.06	22.73	8.03	9.62
Paid Up Equity Share Capital (FV of Rs 10 each)	1010.00	1010.00	1010.00	1010.00	1010.00	1010.00
X. Earning per equity share						
(1) Basic	0.11	0.06	0.02	0.23	0.08	0.10
(2) Diluted	0.11	0.06	0.02	0.23	0.08	0.10

Notes

- 1) The above results for the quarter and half year ended 31 December 2021 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 14th February, 2022. The Statutory Auditors carried out limited review and have expressed an unmodified opinion.
- 2) The operations of the Company relate to two segments viz., Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.

Segment Information:

Particulars	Quarter ended			Nine months ended		Year Ended
	31-12-2021	30-09-2021	31-12-2020	31-12-2021	31-12-2020	31-03-2021
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Segment Revenue						
a) Manufacturing and Trading of Pharma drugs	30.02	-	28.97	30.02	15.85	43.70
b) Consultancy Services	7.43	18.58	(10.43)	44.36	44.56	53.90
Total Sales	37.45	18.58	18.54	74.38	60.41	97.60
Less: Inter Segment Revenue	-	-	-	-	-	-
Total Revenue from Operations	37.45	18.58	18.54	74.38	60.41	97.60
Segment Result (Profit Before Tax and Interest from each Segment)						
a) Manufacturing and Trading of Pharma drugs	6.65	-	1.53	6.65	1.59	2.58
b) Consultancy Services	4.19	6.40	0.24	16.20	6.99	9.25
Total	10.84	6.40	1.77	22.85	8.58	11.83
Less: Interest	-	-	-	-	0.81	1.79
Total Profit before tax	10.84	6.40	1.77	22.85	7.77	10.04
Capital employed (Segment assets - segment liabilities)						
Segment assets						
a) Manufacturing and trading of Pharma drugs	279.54	287.49	331.39	279.54	331.39	298.31
b) Consultancy Services	877.90	855.64	841.04	877.90	841.04	841.37
Total Assets	1,157.44	1,143.13	1,172.43	1,157.44	1,172.43	1,139.68
Segment liabilities						
a) Manufacturing and trading of Pharma drugs	17.20	21.01	43.79	17.20	43.79	19.63
b) Consultancy Services	1.40	0.41	16.16	1.40	16.16	3.95
Total Liabilities	18.60	21.42	59.95	18.60	59.95	23.58

- 3) The Company has considered the possible effects that may result from the pandemic relating to Covid-19 in the preparation of these financial statements including the recoverability of carrying amounts of financial and non-financial assets. In developing the assumptions relating to the possible future uncertainties in the global economic conditions because of this pandemic, the Company has, at the date of approval of these financial statements, used internal and external sources of information including credit reports and related information and economic forecasts and expects that the carrying amount of these assets will be recovered. The impact of Covid-19 on the Company's financial statements may differ from that estimated as at the date of approval of these financial statements.

- 4) Comparative figures have been regrouped/reclassified to conform to the current period's/year's presentation.

For and on behalf of the Board



Sushant Mohan Lal
Director
DIN: 01227151



Place: Hyderabad
Date: 14.02.2022



Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Review Report to The Board of Directors Decipher Labs Limited
(Formerly Known as Combat Drugs Limited)

1. We have reviewed the accompanying statement of Standalone Unaudited Financial Results of Decipher Labs Limited (the Company) for the quarter and nine months ended 31st December, 2021 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ramanatham & Rao
Chartered Accountants
(Firm Regn.No.029345)

K SREENIVASAN

Partner

Membership Number: 206421

UDIN: 22206421ACFBBD8985

Place: Secunderabad

Date: 14th February, 2022

